Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4352815 | Neuroscience Research | 2009 | 9 Pages |
Abstract
Valproic acid (VPA), a drug used to treat epilepsy and bipolar mood disorder, inhibits histone deacetylase (HDAC), which is associated with the epigenetic regulation of gene expression. Using a microarray, we comprehensively examined which genes are affected by stimulating cultured rat cortical neurons with VPA, and found that the VPA-treatment markedly altered gene expression (up-regulated; 726 genes, down-regulated; 577 genes). The mRNA expression for brain-derived neurotrophic factor (BDNF) and the α4 subunit of the GABAA receptor (GABAARα4), known to be involved in epileptogenesis, was up-regulated, with the increase in BDNF exon I-IX mRNA expression being remarkable, whereas that for GABAARγ2, GAD65 and 67, and the K+/Clâ co-transporter KCC2, which are responsible for the development of GABAergic inhibitory neurons, was down-regulated. The number of GAD67-positive neurons decreased upon VPA-treatment. Similar changes of up- and down-regulation were obtained by trichostatin A. VPA did not affect the intracellular Ca2+ concentration and the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), suggesting its direct action on HDAC. The acetylation of histones H3 and H4 was increased in the promoters of up-regulated but not down-regulated genes. Thus, VPA may disrupt a balance between excitatory and inhibitory neuronal activities through its epigenetic effect.
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
Mamoru Fukuchi, Takuya Nii, Naoki Ishimaru, Aya Minamino, Daichi Hara, Ichiro Takasaki, Akiko Tabuchi, Masaaki Tsuda,